SDS Biotech K.K. Reports Consolidated Earnings Results for the Six Months Ended September 30, 2017; Provides Earnings Guidance for the Fiscal Year Ending March 31, 2018
SDS Biotech K.K. reported consolidated earnings results for the six months ended September 30, 2017. For the quarter, the company reported net sales of ¥6,442 million against ¥5,618 million a year ago. Operating income was ¥73 million against operating loss of ¥183 million a year ago. Ordinary income was ¥71 million against ordinary loss of ¥363 million a year ago. Net loss attributable to owners of parent was ¥111 million or ¥14.17 per basic share against ¥127 million or ¥16.25 per basic and diluted share a year ago. Income before income taxes was ¥69,636,000 compared to loss of ¥362,860,000 a year ago. Net cash provided operating activities of ¥869,253,000 compared to net cash used in operating activities of ¥202,114,000 a year ago. Purchase of property, plant and equipment was ¥107,370,000 compared to ¥93,345,000 a year ago. Purchase of intangible assets was ¥12,127,000 compared to ¥17,013,000 a year ago.
For the fiscal year ending March 31, 2018, the consolidated company expects net sales of ¥15,860 million, operating income of ¥1,440 million, ordinary income of ¥1,320 million and net income of ¥630 million or ¥80.45 per share.